Maitake (Grifola frondosa) vs. cancer

Maitake D (MD)-Fraction is a highly purified soluble β-glucan derived from Grifola frondosa (an oriental edible mushroom). Intraperitoneal (i.p.) injection of MD-Fraction has been reported to inhibit tumor growth via enhancement of the host immune system. In this study, we demonstrated that oral administration of MD-Fraction as well as i.p. injection significantly inhibited tumor growth in murine tumor models. After oral administration, MD-Fraction was not transferred to the blood in its free form but was captured by antigen-presenting cells such as macrophages and dendritic cells (DCs) present in the Peyer’s patch. The captured MD-Fraction was then transported to the spleen, thereby inducing the systemic immune response. Our study showed that MD-Fraction directly induced DC maturation via a C-type lectin receptor dectin-1 pathway. The therapeutic response of orally administered MD-Fraction was associated with (i) induced systemic tumor-antigen specific T cell response via dectin-1-dependent activation of DCs, (ii) increased infiltration of the activated T cells into the tumor and (iii) decreased number of tumor-caused immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. Our preclinical study suggests that MD-Fraction is a useful oral therapeutic agent in the management of patients with cancer.

In summary, our results demonstrated that orally administered MD-Fraction inhibits tumor growth by (i) inducing the systemic tumor-antigen specific T cell response via the dectin-1 dependent activation of DCs, (ii) increasing the infiltration of the activated T cells into the tumor and (iii) decreasing tumor-linked immunosuppressive elements such as Tregs and MDSCs. Our preclinical study advocates the implementation of MD-Fraction as an oral therapeutic agent in the management of patients with cancer.

Medicinal mushrooms: Reishi / Linghzi vs. Hepatitis B, cancer, tumors, inflammation

Reishi vs. Hepatitis B

The polysaccharide fractions and triterpenes isolated from Ganoderma lucidum have shown protection effects on the liver in animal studies. This double-blind, randomised, and multicentered study aimed to evaluate the safety and effect of a G. lucidum extraction, Ganopoly, in chronic hepatitis B. Ninety patients with chronic hepatitis B, hepatitis В viral (HBV) DNA positivity, and aminotransferase elevation were included in this multicenter prospective randomized Phase I/II study. Patients were randomized to be given Ganopoly (n = 60) or placebo (n = 30) for 12 weeks, then followed up for 13 weeks. Effect of therapy on levels of HBV DNA and aminotransferase activities in serum and hepatitis В е antigen (HBeAg) status were investigated. There were 78 assessable patients who entered the trial for efficacy and safety; 13 of 52 (25%) patients receiving Ganopoly responded by reducing HBeAg and HBV DNA, compared to 1 of 26 (4%) in the control group (P < 0.05). Among those with serum aspartate aminotransferase (AST) values < 100 U/L (n = 29), 41% (12/29) responded, and among those with AST values > 100 U/L (n = 23), 65% (15/23) responded. Within the 6-month study period, 33% (17/ 52) of treated patients had normal aminotransferase (ALT) values, and 13% (7/52) had cleared hepatitis B surface antigen (HBsAg) from serum, whereas none of the controls had normal ALT values or had lost HBsAg. Eight of 60 patients in Ganopoly group and 4 of 30 in the controls were unable to be followed up due to loss or withdrawal. Our study indicates that Ganopoly is well tolerated and appears to be active against HBV in patients with chronic hepatitis B.,72e968661ff5d957,09001a9418679e96.html

Reishi vs. Hepatitis B (II)

Herbal medicines are always considered to be a safe and useful approach for the treatment of chronic hepatopathy. Ganoderma luciudm (Curt.:Fr.) P. Karst. [(Ling Zhi, Reishi mushroom) (Aphyllophoromycetideae)], a highly ranked medicinal mushroom in Oriental traditional medicine, has been widely used for the treatment of chronic hepatopathy of various etiologies. Data from in vitro and animal studies indicate that G. lucidum extracts (mainly polysaccharides or triterpenoids) exhibit protective activities against liver injury induced by toxic chemicals (e.g., CCl4) and Bacillus Calmette-Guerin (BCG) plus lipopolysaccharide (LPS). G. lucidum also showed anti–hepatitis B virus (HBV) activity in a duckling study. Recently, a randomized placebo-controlled clinical study showed that treatment with G. lucidum polysaccharides for 12 weeks reduced hepatitis B e antigen (HBeAg) and HBV DNA in 25% (13/52) patients with HBV infection. The mechanisms of the hepatoprotective effects of G. lucidum have been largely undefined. However, accumulating evidence suggests several possible mechanisms. These include antioxidant and radical-scavenging activity, modulation of hepatic Phase I and II enzymes, inhibition of b-glucuronidase, antifibrotic and antiviral activity, modulation of nitric oxide production, maintenance of hepatocellular calcium homeostasis, and immunomodulating effects. G. lucidum could represent a promising approach for the management of various chronic hepatopathies. Further studies are needed to explore the kinetics and mechanisms of action of G. lucidum constituents with hepatoprotective activities.,3389befb6be7818a,3ea891d772a09d0f.html

Reishi vs. tumors

Ganoderma lucidum has been established to be an antitumor natural product. Hot-water extracts of the mycelium of G. lucidum (GLP) exhibited antitumor effect against fibrosarcoma in male and female C3H mice and inhibited the metastasis of the tumor to the lung. Moreover, we have fractionated GLP into polysaccharide fraction [GLP(AI)] and nonpolysaccharide fraction. We found that GLP(AI) is the major component to show the in vivo antitumor effect on fibrosarcoma growth in C3H mice. The effect of PS-G purified from GLP(AI) by Sephadex and ion-exchange column chromatography on the induction of differentiation in leukemic U937 cells was examined. We found that it could stimulate blood mononuclear cells to secrete cytokines, TNF-a, IFN-g, IL-1b, and IL-6, etc., which were both antiproliferative and differentiation-inductive to the leukemic U937 and HL-60 cells. TNF-a and IFN-g, especially, induced apoptosis and differentiation in the treated leukemic cells. Furthermore, antitumor activity of G. lucidum on intraperitioneally implanted Lewis lung carcinoma in syngeneic C57BL/6 mice was investigated. The results showed that GLP significantly increased the lifespan of tumor-implanted mice, when administered intraperioneally alone or in combination with cytotoxic antitumor drugs (adriamycin, fluorouracil, thioguanine, methotrexate, or cisplatin) or a synthetic immunomodulator (imexon). The GLP was not cytotoxic to cultured cells, and the antitumor activity was abolished by pretreatment of mice with cyclosporine. These observations suggest that GLP exerts its antitumor effect mainly through immunopotentiation of the tumor-bearing animals.,58cadf0c6c913237,1af485045b17e424.html

Reishi vs. tumors and inflammation

A series of lanostane-type triterpene acids, including eleven lucidenic acids (3, 4, 9, 10, 13–19) and six ganoderic acids (20–22, 24, 26, 27), as well as six sterols (28–33), all isolated from the fruiting bodies of the fungus Ganoderma lucidum, were examined for their inhibitory effects on the induction of Epstein–Barr virus early antigen (EBV-EA) by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells, a known primary screening test for anti-tumor promoters. All of the compounds tested, except for ganolactone (27) and three sterols (29–31), showed potent inhibitory effects on EBV-EA induction, with IC50 values of 235–370 mol ratio/32 pmol TPA. In addition, nine lucidenic acids (1, 2, 5–8, 11, 12, 18) and four ganoderic acids (20, 23–25) were found to inhibit TPA-induced inflammation (1 μg/ear) in mice, with ID50 values of 0.07–0.39 mg per ear. Further, 20-hydroxylucidenic acid N (18) exhibited inhibitory effects on skin-tumor promotion in an in vivo two-stage mouse-skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator, and with TPA as promoter.

Reishi vs. cancer

The meta-analysis results showed that patients who had been given G. lucidum alongside with chemo/radiotherapy were more likely to respond positively compared to chemo/radiotherapy alone (RR 1.50; 95% CI 0.90 to 2.51, P = 0.02). G. lucidum treatment alone did not demonstrate the same regression rate as that seen in combined therapy. The results for host immune function indicators suggested that G. lucidum simultaneously increases the percentage of CD3, CD4 and CD8 by 3.91% (95% CI 1.92% to 5.90%, P < 0.01), 3.05% (95% CI 1.00% to 5.11%, P < 0.01) and 2.02% (95% CI 0.21% to 3.84%, P = 0.03), respectively. In addition, leukocyte, NK-cell activity and CD4/CD8 ratio were marginally elevated. Four studies showed that patients in the G. lucidum group had relatively improved quality of life in comparison to controls. One study recorded minimal side effects, including nausea and insomnia. No significant haematological or hepatological toxicity was reported.

Our review did not find sufficient evidence to justify the use of G. lucidum as a first-line treatment for cancer. It remains uncertain whether G. lucidum helps prolong long-term cancer survival. However, G. lucidum could be administered as an alternative adjunct to conventional treatment in consideration of its potential of enhancing tumour response and stimulating host immunity. G. lucidum was generally well tolerated by most participants with only a scattered number of minor adverse events. No major toxicity was observed across the studies. Although there were few reports of harmful effect of G. lucidum, the use of its extract should be judicious, especially after thorough consideration of cost-benefit and patient preference. Future studies should put emphasis on the improvement in methodological quality and further clinical research on the effect of G. lucidum on cancer long-term survival are needed. An update to this review will be performed every two years.

Where to buy medicinal mushrooms? Order mushroom extracts from China

What you should know about medicinal mushroom extracts:

– buy only hot water mushroom extracts OR alcohol mushroom extracts
– avoid powdered mushroom because your body will not digest “chitin”
– avoid powdered mushrooms because they almost don’t have any active ingredients
– hot water extraction is the only way for breaking polysaccharides out of indigestible mushroom cells
– seriously, powdered mushrooms are not better than “placebo”
– only extraction provides concentrated polysaccharides
– only extraction provides good concentration of bioavailable ingredients
– read this article about five major medicinal mushrooms: “Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology”

Where to buy good quality medicinal mushrooms extracts?

There are many companies selling “food suplements” with medicinal mushrooms. Unfortunetly they are extremly overpriced and often contain powdered mushrooms instead of mushroom extracts. Many companies sell products that are not better than “placebo”. It’s because your body will not digest chitin from powdered mushrooms.

Fortunetly you can order mushroom extracts from China.

A few months ago I was looking for a good bio-technology company from China. I’ve requested informations from 15-20 sellers available on AliBaba and AliExpress. That’s how I found XI’AN NATE BIOLOGICAL TECHNOLOGY CO.,LTD.

They gave me the answers to all my questions and they had real knowledge about mushroom extracts. That’s why I decided to buy Coriolus Versicolor (Trametes Versicolor) extract from them. I paid via Western Union and a few days later I got my package, via FedEx, without any problems.

That’s why I decided to share my knowledge with you and I asked them for actual price list for all medicinal mushrooms extracts.

Prices below are for 200 kgs, but you can order 1 kg too. Of course the price for 1 kg will be higher.

Item name Specifications / Active ingredients USD/kg FOB
Chaga mushroom extract (from fruiting body) Polysaccharide>40%,triterpene>2%, Betulinic acid >2% 200kg $ 74.0/kg

Polysaccharide>20%,triterpene>6% 200kg $ 132.0/kg
Reishi mushroom spore powder Wall broken ratio>98% 200kg $55.0/kg
Reishi mushroom extract (from fruiting body) Polysaccharide>30%,triterpenoid>2% 200kg $57.0/kg

Polysaccharide>40%,triterpenoid>2% 200kg $70.0/kg
Polysaccharide>10%,triterpenoid>4% 200kg $86.0/kg
Polysaccharide>10%,triterpenoid>8% 200kg $125.0/kg
Cordycep sinensis extract(CS-4 mycelium) Polysaccharide>30%,Adenosine 0.5 200kg $65.0/kg
 Polysaccharide>40%,Adenosine 1.0 200kg $74.0/kg
Cordyceps militaris extract (from fruiting body) Polysaccharide>40%,Adenosine 0.5 200kg $ 73.0/kg

Polysaccharide>50%,Adenosine 1.0 200kg $ 85.0/kg
Polysaccharide>20%,Cordycepin 1.0% 200kg $ 97.0/kg
Polysaccharide>15%,Cordycepin 3.0% 200kg $ 302.0/kg
Lion’s mane mushroom extract (from fruiting body) Polysaccharide>40% 200kg $ 64.0/kg
 Polysaccharide>50% 200kg $ 75.0/kg
Coriolus versicolor / Turkey tail extract Polysaccharide>40% 200kg $ 65.0/kg
 Glycopeptide 30%,protein 10% 200kg $ 86.0/kg
Shiitake mushroom extract (from fruiting body)

Polysaccharide>40% 200kg $54.0/kg
 Polysaccharide>50% 200kg $62.0/kg
Maitake mushroom extract Polysaccharide>40% 200kg $ 67.0/kg
Maitake mushroom extract MD>30%,Protein10% 200kg


Agaricus blazei extract Polysaccharide>40% 200kg $ 55.0/kg
Phellinus igniarius extract (from fruiting body)

Polysaccharide>20%,triterpenoid>1% 200kg


 Polysaccharide>40%,triterpenoid>2% 200kg


Tremella fuciformis extract Polysaccharide>40% 200kg


Enoki mushroom extract Polysaccharide>40% 200kg


Coprinus comatus extract Polysaccharide>40% 200kg


Agrocybe cylindraceaextract Polysaccharide>40% 200kg


Antrodia Camphorata extract Polysaccharide>40% 200kg


Poria cocos extract

Polysaccharide>40% 200kg


Polyporus umbellatus extract Polysaccharide>40% 200kg






Agaricus bisporus extract Polysaccharide>40%



Chantarelle extract Polysaccharide>40%



Boletus edulis extract Polysaccharide>40%



Reishi (Ganoderma Lucidum) vs. cancer

The mushroom Ganoderma lucidum (G. lucidum) has been used for centuries in Asian countries to treat various diseases and to promote health and longevity. Clinical studies have shown beneficial effects of G. lucidum as an alternative adjuvant therapy in cancer patients without obvious toxicity. G. lucidum polysaccharides (GLP) is the main bioactive component in the water soluble extracts of this mushroom. Evidence from in vitro and in vivo studies has demonstrated that GLP possesses potential anticancer activity through immunomodulatory, anti-proliferative, pro-apoptotic, anti-metastatic and anti-angiogenic effects. Here, we briefly summarize these anticancer effects of GLP and the underlying mechanisms.


Consumption of reishi mushroom has been reported to prevent colon carcinogenesis in rodents, although the underlying mechanisms remain unclear. To investigate this effect, rats were fed a high-fat diet supplemented with 5% water extract from either the reishi mushroom (Ganoderma lingzhi) (WGL) or the auto-digested reishi G. lingzhi (AWGL) for three weeks. Both extracts markedly reduced fecal secondary bile acids, such as lithocholic acid and deoxycholic acid (colon carcinogens). These extracts reduced the numbers of Clostridium coccoides and Clostridium leptum (secondary bile acids-producing bacteria) in a per g of cecal digesta. Fecal mucins and cecal propionate were significantly elevated by both extracts, and fecal IgA was significantly elevated by WGL, but not by AWGL. These results suggest that the reishi extracts have an impact on colon luminal health by modulating secondary bile acids, microflora, mucins, and propionate that related to colon cancer.


The medical mushroom Ganoderma lucidum (Reishi), a traditional Chinese medicine, has exhibited a promising anti-cancer effect. However, the molecular mechanism of its action on cancer cells remains unclear. Aberrant activation of Wnt/β-catenin signaling pathway is the cause of many types of cancer, including breast cancer. Here we investigated the effect of Reishi on Wnt/β-catenin signaling pathway and elucidated the molecular mechanism of its function in inhibiting breast cancer cells. We found that Reishi blocked Wnt/β-catenin signaling through inhibiting the phosphorylation of Wnt co-receptor LRP6. In human (MDA-MB-231) and mouse (4T1) breast cancer cell lines, Reishi significantly decreased the phosphorylation of LRP6 and suppressed Wnt3a-activated Wnt target gene Axin2 expression. Administration of Reishi inhibited Wnt-induced hyper-proliferation of breast cancer cells and MDA-MB-231 cell migration. Our results provide evidence that Reishi suppresses breast cancer cell growth and migration through inhibiting Wnt/β-catenin signaling, indicating that Reishi may be a potential natural inhibitor for breast cancer.


The present study investigated the anticancer effects and potential mechanisms of BSGLWE on colorectal cancer in vivo and in vitro. Our results showed that BSGLWE significantly inhibited colorectal cancer HCT116 cell viability in a time- and dose-dependent manner. Flow cytometry analysis indicated that BSGLWE disrupted cell cycle progression at G2/M phase via downregulation of cyclin B1 and cyclin A2, and upregulation of P21 at mRNA levels. Moreover, BSGLWE induced apoptosis by decreasing Bcl-2 and survivin at mRNA levels, and reduced Bcl-2, PARP, pro-caspase-3 and pro-caspase-9 at protein levels. Furthermore, BSGLWE suppressed tumor growth in vivo by regulating the expression of genes and proteins associated with cell cycle and apoptosis, which was further confirmed by a reduction of Ki67, PCNA, and Bcl-2 expression as determined by immunohistochemistry staining. NSAID activated gene-1 (NAG-1), a pro-apoptotic gene, was significantly upregulated in vivo and in vitro upon BSGLWE treatment at both mRNA and protein levels. In addition, the relative amounts of secreted NAG-1 in cell culture medium or serum of nude mice were all upregulated upon BSGLWE treatments, suggesting a role of NAG-1 in BSGLWE-induced anticolorectal cancer activity. This is the first study to show that BSGLWE inhibits colorectal cancer carcinogenesis through regulating genes responsible for cell proliferation, cell cycle and apoptosis cascades. These findings indicate that BSGLWE possesses chemopreventive potential in colorectal cancer which may serve as a promising anticancer agent for clinical applications.


The aim of this study is to investigate the anti-inflammatory, anticancer and anti-metastatic activities of Ganoderma lucidum extracts in melanoma and triple-negative breast cancer cells. Ganoderma lucidum extracts were prepared by using common organic solvents; MDA-MB 231 and B16-F10 cell lines were adopted as cellular models for triple-negative breast cancer and melanoma and characterized for cell viability, wound-healing assay and measurement of cytokines secreted by cancer cells under pro-inflammatory conditions (incubation with lipopolysaccharide, LPS) and pretreatment with Ganoderma lucidum extract at different concentrations. Our study demonstrates, for the first time, how Ganoderma lucidum extracts can significantly inhibit the release of IL-8, IL-6, MMP-2 and MMP-9 in cancer cells under pro-inflammatory condition. Interestingly, Ganoderma lucidum extracts significantly also decrease the viability of both cancer cells in a time- and concentration-dependent manner, with abilities to reduce cell migration over time, which is correlated with a lower release of matrix metalloproteases. Taken together, these results indicate the possible use of Ganoderma lucidum extract for the therapeutic management of melanoma and human triple-negative breast cancer.


G. lucidum polysaccharides – mainly β-glucans and heteroglycans – have numerous biological properties such as antitumour and immunomodulatory activities. This report shows, by gene expression analyses and bioenergetic assays, immunomodulatory properties and capacity to improve glucose metabolism of a water-soluble heteroglycan extracted from mycelium of an Italian isolate of G. lucidum. The findings suggest the use of the heteroglycan as probiotic or ingredient in functional foods, being easy to produce and disperse in a food matrix thanks to its water-solubility. Heteroglycan could exert protective effects in pro-inflammatory conditions and benefits for people characterised by suppressed immune response.

HPV treatment – HPV cure research 2018

Prologue: How to deal with HPV?

A) Don’t PANIC!
B) Learn about HPV from reliable sources, for example:
C) Don’t waste your money on food supplements without any clinical trials (like Echinacea, Astralagus, Zinc…)

There is no cure for HPV but you can still fight with the virus.

How to get rid of HPV faster?

1) Quit smoking
2) Quit drinking
3) Check glucose level in your blood – there is a correlation between HPV strength/recurrence of genital warts (if you have HPV6/11) and diabetes.
4) Eat healthy food, eat lots of vegetables
5) Lower your sugar/carbohydrates intake. Cancer and HPV love sugar.
6) Exercise 2-3 times per week
7) You can try medicinal mushrooms:
– Coriolus versicolor boost immune system
– Reishi fights directly with HPV* and cancer cells*
– Chaga has strong anti-viral activity

IMPORTANT: buy only alcohol/water reishi extracts because they have active ingredients. Avoid powdered reishi – it’s not better than placebo.

– Lentinan (from shiitake mushrooms) lowers genital warts recurrence

* – In this study, we investigated the effects of the aqueous extracts of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum, obtained from three localities (China; and Morelos and Michoacan, Mexico) on cervical cells transformed by human papillomavirus (HeLa and SiHa) and C-33A cancer cells. The cells were plated in DMEM medium supplemented, and were incubated in the presence of different concentrations of G. lucidum for 24 h. Cell proliferation was determined by MTT colorimetric assay and viability by trypan blue assay. Inhibitory dose was determined (IC50) of the three different extracts of G. lucidum in the culture cell lines mentioned above. The apoptosis process was confirmed by nuclear DNA fragmentation and the cell cycle was determined by flow cytometry. The results showed that aqueous extracts G. lucidum obtained from three localities produced inhibition in the proliferation of VPH transformed cells; they also induced apoptosis and cell cycle arrest in HeLa, SiHa, and C-33A cancer cells. Therefore, it was found that aqueous extracts G. lucidum obtained from three different locations produced inhibitory effect on cancer cells and may have a potential therapeutic use for the prevention and treatment of this disease.

8) Vaccine yourself against HPV – it will not help your current infection, but it can protect you against other HPV strains. The best vaccine is called “Gardasil” and “Gardasil 9”.

How to get rid of genital warts?

You can try:
– Podophyllotoxin (it’s very effective, very fast, but you can get skin infection)
– Imiquimod/Aldara (it’s an immunomodulator, you will wait longer to see the effects; Imiquimod is much less effective in case of men)
– Veregen (it’s a green tea extract, it’s effective but very expensive; you will wait very long to see the effects)
– Panavir (antiviral medicine made in Russia; it’s available i.e. as a gel)
– combine Cryotherapy or Podophyllotoxin with Inosine Pranobex (antiviral medicine)

You can ask your doctor for:
– electrocauterization (it’s painful)
– laser treatment
– cryotherapy (the fastest and the cheapest option)
– photodynamic therapy (the best option but it’s hard to get photodynamic therapy against genital warts; many dermatologists don’t know that photodynamic therapy can be used against genital warts)

In general the best options for HPV are:
– check your glucose level and avoid junk food/sugar
– take medicinal mushrooms – Coriolus versicolor 3g/daily in the morning, Reishi (Lingzhi) 1-2g/daily in the evening.,266d4152107fca7a,3512deba5cc9e72b.html
– take Ellagic acid and Annona Muricata extract (check details below)

In general the best options for HPV genital warts are as above, and additionally:
– use Podophyllotoxin for small warts
– use Cryotherapy for big warts
– try to get Photodynamic Therapy
– try Panavir, it’s very effective in combined therapy, when i.e. Cryotherapy removes the warts, and Panavir lowers the chances of recurrences
– combine Cryotherapy or Podophyllotoxin with Inosine Pranobex


2018 UPDATE:

Hyperthermia vs. HPV and genital warts

In the current report, the investigators demonstrate that APOBEC3A and APOBEC3G expression levels are increased in genital warts (condyloma acuminata) compared with normal tissues, in which APOBEC3G is barely detectable (Yang et al., 2017). On heat treatment to 42 °C and 45 °C, there is a significant increase in APOBEC3A and APOBEC3G mRNA transcripts in condyloma acuminate, up to 10-fold. Again, this effect is not observed in normal skin.

Although hyperthermia is not as widely used as cryotherapy in treating warts, including genital warts, it is interesting to note that hyperthermia seems to have an advantage as it is not destructive, but, rather, appears to stimulate antiviral and immunological pathways that are reminiscent of the use of imiquimod. This study provides an elegant explanation for the observed clinical effects of hyperthermia on warts. What is unclear is whether APOBEC3A and APOBEC3G expression contribute not only to editing HPV and limiting its replication, but also whether these mutations increase immune responses against the virus. Hyperthermia, in contrast to cryotherapy, would be an elegant way to expose the virus in a meaningful way to immune reactivity and even prevent recurrences, an effect similar to that of imiquimod when used to treat genital warts.

Ellagic acid and Annona Muricata vs. HPV and L-SIL

Ellagic acid (EA) and Annona Muricata (AM) have antioxidant, anticarcinogenic and antiviral activity demonstrated by in vitro models. This pilot study investigated the in vivo potential anti-viral activity in women affected by Low squamous intraepithelial lesion (L-SIL) related to high risk human papilloma virus (HR-HPV), and the ability to modify the oncoproteins expression in the cervical lesion thickness. Sixty women affected by HR-HPV related L-SIL, were randomly divided into two groups: group A (n = 30) supplemented with EA (16 mg) + AM (100 mg) 2 times daily for 6 months and group B (n = 30) administered with placebo. HR-HPV clearance was obtained in 74% of cases in group A compared to 25% of cases in group B (p = 0.001) and p21 expression in LSIL thickness increased in 63.2% of cases in group A compared to 20% in group B (p = 0.03). AE/AM supplementation significantly induces HR-HPV elimination and stimulates p21 expression in LSIL thickness.

2018 UPDATE 2:

Check clinical trials about Panavir, antiviral medicine made in Russia:


2018 UPDATE 3:

Combine Cryotherapy or Podophyllotoxin (to remove warts) with Inosine Pranobex (to lower recurrences):

This study evaluates the effectiveness of immunomodulating drug isoprinosine in a comprehensive treatment of genital warts in men. Most of the patients were aged 20-30 years. The combination therapy was found to have long term effectiveness. In the group of patients undergoing only destructive methods of treatment relapse after 8 month follow-up was diagnosed in 32% and in patients of the combination therapy group (destruction plus isoprinosine) – in 7% of patients. The pharmacological action of the drug (immunostimulating, antiviral) and the effectiveness of its combination with destructive therapies justify the use of inosine pranobex (isoprinosine) both in the complex therapy of genital warts and for the prevention of the disease recurrence.


Lentinan from shiitake mushrooms vs. HPV

Objective: To observe the immunomodulatory and therapeutic effect of lentinan in treating condyloma acuminatum (CA).Methods: Thirty-six CA patients were randomly divided into two groups, 19 in the treated group treated with lentinan and CO2 laser irradiation, and 17 in the control group, treated with laser irradiation alone. Their T lymphocyte subsets of peripheral blood and level of serum interleukin-2 (IL-2) and soluble interleukin-2 receptor (SIL-2R) were determined before and after treatment, and the recurrence rates of the two groups were compared.Results: After treatment, in the treated group, the CD4/CD8 ratio, serum IL-2 raised and serum SIL-2R lowered significantly (P < 0.05, 0.05, 0.05 respectively) as compared with before treatment, while those parameters were not changed significantly in the control group. The recurrence rate of the treated group was lower than that of the control group.P < 0.05.Conclusion: Lentinan could modulate the cellular immunofunction of CA patients and reduce the recurrence rate of CA cases.

Comparison of Recurrence Rate of Two Groups after Treatment:

Ten among 36 cases showed recurrence, the recurrence rate was 27.78%; among them, 2 of the treated group were recurrent, the recurrence rate was 10.53%; while that of the control group [the recurrence rate] was 47.06% (8/17 cases). The difference of the recurrence rate of two groups was significiant.

Check the whole clinical trial: Immunomodulatory and therapeutic effect of lentinan in treating condyloma acuminatum

Medicinal mushrooms and cancer – a scientific review

From time immemorial, mushrooms have been valued by humankind as a culinary wonder and folk medicine in Oriental practice. The last decade has witnessed the overwhelming interest of western research fraternity in pharmaceutical potential of mushrooms. The chief medicinal uses of mushrooms discovered so far are as anti-oxidant, anti-diabetic, hypocholesterolemic, anti-tumor, anti-cancer, immunomodulatory, anti-allergic, nephroprotective, and anti-microbial agents. The mushrooms credited with success against cancer belong to the genus Phellinus, Pleurotus, Agaricus, Ganoderma, Clitocybe, Antrodia, Trametes, Cordyceps, Xerocomus, Calvatia, Schizophyllum, Flammulina, Suillus, Inonotus, Inocybe, Funlia, Lactarius, Albatrellus, Russula, and Fomes. The anti-cancer compounds play crucial role as reactive oxygen species inducer, mitotic kinase inhibitor, anti-mitotic, angiogenesis inhibitor, topoisomerase inhibitor, leading to apoptosis, and eventually checking cancer proliferation. The present review updates the recent findings on the pharmacologically active compounds, their anti-tumor potential, and underlying mechanism of biological action in order to raise awareness for further investigations to develop cancer therapeutics from mushrooms. The mounting evidences from various research groups across the globe, regarding anti-tumor application of mushroom extracts unarguably make it a fast-track research area worth mass attention.

Read the whole raport: Recent developments in mushrooms as anti-cancer therapeutics: a review

The best medicinal mushrooms – list, benefits, anti-cancer mushrooms


  • Reishi
  • Coriolus versicolor
  • Shiitake
  • Monkeyhead mushroom
  • Agaricus blazei
  • Chaga
  • Cordyceps sinensis

Reishi extract

Ganoderma lucideum

Fruitbody, Mycelium

Polysaccharides, BETA D Glucan, Triterpene, Protein, Reishi acid

Protect liver
Strengthen immunity
Promote the synthetic ability of DNA, RNA and protein in the liver, bone marrow and blood

Lions mane / Monkeyhead mushroom extract

Hericium erinaceus

Fruitbody, mycelium

Polysaccharides, BETA D Glucan, Hericenones

Help to cure dyspesia, gastric ulcer, stomachache gasteremphraxis and neurasthenia
Lower serum cholesterol
Promote blood circulation

Agaricus blazei extract

Agaricus brasilensis

Fruitbody, mycelium

Polysaccharides, BETA D Glucan, Triterpene, Glycopeptide

Retrain tumor cell growth
Lower blood glucose and cholesterol
Reverse atherosclerosis
Anti-tumor, anti-radiation
Resist mutation and anti-inflammatory

Coriolus versicolor / Turkey Tail

Trametes versicolor

Fruitbody, mycelium

Polysaccharides, BETA D Glucan, Triterpene, Glycopeptite, Protein

Protect liver and heart
Cure chronic hepatitis and hepatitis B
Enhance body immunity

Shiitake extract

Lentinus edodes

Fruitbody, Mycelium

Polysaccharides, BETA D Glucan, Adenosine

Relieve symptoms of relapsed gastric cancer, liver cancer, bladder canber.
Enhance body immunity system.
Adjust disorder of trace emements.

Chaga extract

Inonqqus obliquus

Fruitbody, mycelium

Polysccharides, BETA D Glucan, Triterpene, Betulinic acid

Lower blood glucose
Help to cure heart diseases, diabetes, cancer (gastric cancer, liver cancer, lung cancer)
Restrain HIV virus

Cordyceps sinensis extract

Ophiocordyceps sinensis

Mycelium, dried cordyceps militaris

Polysaccharides, Manitol, Adenosine, Cordycepin, Cordycepic acid

Improve respiratory system
Enhance body immunity
Promote adrenal gland

Medicinal mushrooms vs. cancer – clinical trials

This review discusses the immunological roles of 5 major mushrooms in oncology: Agaricus blazei, Cordyceps sinensis, Grifola frondosa, Ganoderma lucidum, and Trametes versicolor. These mushrooms were selected based on the body of research performed on mushroom immunology in an oncology model. First, this article focuses on how mushrooms modify cytokines within specific cancer models and on how those cytokines affect the disease process. Second, this article examines the direct effect of mushrooms on cancer. Finally, this article presents an analysis of how mushrooms interact with chemotherapeutic agents, including their effects on its efficacy and on the myelosuppression that results from it. For these 5 mushrooms, an abundance of in vitro evidence exists that elucidates the anticancer immunological mechanisms. Preliminary research in humans is also available and is promising for treatment.

Summary of potential clinical applications of medicinal mushrooms:

Type of Cancer Indicated Mushroom
Nonsmall-cell lung cancer Cordyceps
Lung cancer Reishi (ganorderma lucidum)
Gastric cancer PSK (turkey tail/coriolus versicolor)
Hepatocellular carcinoma Agaricus, reishi (ganoderma lucidum)
Leukemia Agaricus, reishi (ganoderma lucidum)
Lymphoma Cordyceps
Breast cancer Reishi, maitake, turkey tail (Coriolus versicolor)
Colon cancer Maitake, reishi, turkey tail (Coriolus versicolor)
Prostate cancer Reishi (ganoderma lucidum)
Sarcoma Reishi (ganoderma lucidum)

PSK = polysaccharide K.
Turkey tail = Coriolus versicolor = Trametes versicolor
Reishi = Ganoderma lucidum

Check the whole review below:

Source: Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology

Coriolus versicolor vs. HPV – clinical trials

Study 1:

In the conservative treatment, 64 out of 73 patients (88% of total) reverted to HPV-negative status;
In the combined treatment, 25 out of 27 patients (93% of total)reverted to HPV-negative status;

Study 2:

95% of the patients reverted to HPV-negative status within 6 months;
HPV-positive patients without histological changes reverted to HPV-negative status in 3 months;

Study 3:

Dr Couto showed that Coriolus versicolor biomass supplementation (3 g per day) over a period of one year substantially increased regression of LSIL (72.5% versus control 47.5%) and induced clearance of the high-risk sub-types of the HPV virus responsible for cervical cancer (90.0% versus control 8.5%).

Check this website for more details: Coriolus versicolor as an Effective Addition to the Treatment of HPV Infection

Study 4:

Effect of tropical mushroom, Coriolus versicolor, on natural killer cell

Here, the authors report observation on a patient with underlying breast cancer after complete standard treatment who intake C. versicolor as food supplementation. At first, her natural killer count (CD16/56) was at 5.9% (normal value 6.4-31.1). She got C. versicolor 2400 mg/day for 1 month, and the follow-up result showed CD16/56 equal to 11.6%. This observation can support the findings that C. versicolor could promote immunity.

Source: Annals of Tropical Medicine and Public Health